Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) and Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends.
Volatility & Risk
Dianthus Therapeutics has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.19, meaning that its share price is 119% less volatile than the S&P 500.
Valuation & Earnings
This table compares Dianthus Therapeutics and Entrada Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dianthus Therapeutics | $2.04 million | 2,333.83 | -$162.34 million | ($3.99) | -21.19 |
| Entrada Therapeutics | $3.98 million | 42.82 | -$143.75 million | ($3.84) | -1.13 |
Entrada Therapeutics has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and target prices for Dianthus Therapeutics and Entrada Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dianthus Therapeutics | 1 | 0 | 13 | 2 | 3.00 |
| Entrada Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
Dianthus Therapeutics presently has a consensus price target of $128.77, indicating a potential upside of 52.30%. Entrada Therapeutics has a consensus price target of $16.75, indicating a potential upside of 285.06%. Given Entrada Therapeutics’ higher probable upside, analysts clearly believe Entrada Therapeutics is more favorable than Dianthus Therapeutics.
Profitability
This table compares Dianthus Therapeutics and Entrada Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dianthus Therapeutics | -7,436.50% | -19.68% | -18.95% |
| Entrada Therapeutics | -4,057.98% | -64.00% | -50.49% |
Insider and Institutional Ownership
47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Entrada Therapeutics beats Dianthus Therapeutics on 8 of the 15 factors compared between the two stocks.
About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company’s research focuses on selectively targeting complement activity that contributes to disease. Dianthus became a publicly traded company in 2023 through a merger with Magenta Therapeutics. Its clinical development activities are intended to support potential use across patient populations, though the company has not established a commercial geographic footprint.
About Entrada Therapeutics
Entrada Therapeutics is a biotechnology company focused on developing medicines that deliver therapeutic molecules into cells. Founded in 2016 and based in Boston, Massachusetts, the company developed its Endosomal Escape Vehicle (EEV) platform to help move drug cargo across cellular membranes and reach intracellular targets. The company’s research centers on its EEV-based oligonucleotide medicines, including programs designed to address genetic causes of neuromuscular diseases. Its development work includes candidates intended to alter RNA processing for Duchenne muscular dystrophy, with programs targeting different genetic subgroups of the disease.
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
